Acomplia News
2006-10-19 06:10:03
... > German state won't subsidise Sanofi-Aventis' Acomplia - committee <th> Article layout: raw FRANKFURT (AFX) - German authorities have decided that the state health-care system shouldn't pay for Acomplia, a new obesity drug viewed as a potential blockbuster for Sanofi-Aventis SA. The Federal Joint Committee of doctors and health-insurance funds said it has classified Acomplia a "lifestyle" drug and therefore ineligible for a price subsidy, the Wall Street Journal reported. The committee did not accept Sanofi's argument that Acomplia should b ...
2006-10-18 14:54:07
Rimonabant (Acomplia) Successful Again in Reducing Weight, WaistEuropean study says it also reduced factors for heart disease in obese peopleApril 15, 2005 - Acomplia. which is still going by its generic name rimonabant, while it awaits FDA approval, has again won accolades for reducing bodyweight, waist circumference, and risk factors for heart disease in obese people, according to results of a randomized trial published in this weeks issue of The Lancet. Read more...Weight Loss Miracle Drug Passes Two-Yea ...
2006-10-18 10:36:03
Weight loss drug Rimonabant, sold under the brand name Acomplia, might not be as effective as it claims to be but can help overweight people lose 'modest' amount of weight, a Brazilian study has found. The drug, however, is yet to be approved by the US Food and Drug Administration (FDA). Under the study, which reviewed four controlled trials of the drug, researchers from State University of Rio de Janeiro took into consideration the effect of Acomplia on around 6,625 adult participants who fell ...
2006-10-17 23:20:12
sponsoredFeatured CentersAcomplia Shows 'Modest' Weight LossCalories Still Count With Weight Loss Drug Acomplia, Review ShowsBy Miranda HittiWebMD Medical NewsReviewed By Louise Chang, MD on Tuesday, October 17, 2006More From WebMDKeeping the Pounds Off: What WorksSmart Diet Tips for DiabeticsAcomplia: A Weight Loss Wonder Drug?Oct. 17, 2006 -- The weight loss drug Acomplia hasn't been approved by the FDA, but it's already drawing attention from the public and scientists.The latest Acomplia headlines appear online in Th ...
2006-10-09 12:00:44
Copyright © 2002 - 2006 newratings.com, a Joint Venture ofNew Ratings Inc. and aktiencheck.de AG | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using Standard&Poor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX. All content copyright newratings.com. All rights reserved. Republication or redistribution strictly prohibited without the prior written consent of newratings.com. In no event ...
You can suggest a news source.